 | Up a level |
Regan, M. M.; Pagani, O.; Walley, B.; Torrisi, R.; Perez, E. A.; Francis, P.; Fleming, G. F.; Price, K. N.; Thürlimann, B.; Maibach, R.; Castiglione-Gertsch, M.; Coates, A. S.; Goldhirsch, A.; Gelber, R. D. (2008). Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Annals of oncology, 19(7), pp. 1231-1241. Oxford University Press 10.1093/annonc/mdn037
Roth, A. D.; Maibach, R.; Fazio, N.; Sessa, C.; Stupp, R.; Morant, R.; Herrmann, R.; Borner, M. M.; Goldhirsch, A.; De Braud, F. (2004). 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)–cisplatin in advanced gastric carcinoma: a phase I–II trial. Annals of oncology, 15(5), pp. 759-764. Oxford University Press 10.1093/annonc/mdh187
Roth, A. D.; Maibach, R.; Martinelli, G.; Fazio, N.; Aapro, M. S.; Pagani, O.; Morant, R.; Borner, M. M.; Herrmann, R.; Honegger, H.; Cavalli, F.; Alberto, P.; Castiglione, M.; Goldhirsch, A. (2000). Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma. Annals of oncology, 11(3), pp. 301-306. Oxford University Press 10.1023/A:1008342013224
